UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

Journal of clinical oncology, 2012-02, Vol.30 (4), p.372-379

2012

Volltextzugriff (PDF)

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

The Lancet (British edition), 2008-11, Vol.372 (9652), p.1809-1818

2008

Volltextzugriff (PDF)

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

The New England journal of medicine, 2018-12, Vol.379 (26), p.2495-2505

2018

Volltextzugriff (PDF)

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2021-12, Vol.22 (12), p.1721-1731

2021

Volltextzugriff (PDF)

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

Journal of clinical oncology, 2023-01, Vol.41 (3), p.609-617

2023

Volltextzugriff (PDF)

Reply to S. Gulia et al

Journal of clinical oncology, 2021-01, Vol.39 (3), p.256-256

2021

Volltextzugriff (PDF)

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

Journal of clinical oncology, 2020-04, Vol.38 (11), p.1164-1174

2020

Volltextzugriff (PDF)

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

British journal of cancer, 2018-10, Vol.119 (9), p.1075-1085

2018

Volltextzugriff (PDF)

Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial

Journal of clinical oncology, 2020-10, Vol.38 (30), p.3528-3537

2020

Volltextzugriff (PDF)

Reply to E. Paulino et al

Journal of clinical oncology, 2020-08, Vol.38 (23), p.2698-2698

2020

Volltextzugriff (PDF)

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Breast cancer research : BCR, 2013-01, Vol.15 (5), p.R88-R88, Article R88

2013

Volltextzugriff (PDF)

Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial

Clinical cancer research, 2022-10, Vol.28 (19), p.4186-4193

2022

Volltextzugriff (PDF)

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

Gynecologic oncology, 2021-10, Vol.163 (1), p.41-49

2021

Volltextzugriff (PDF)

Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study

Gynecologic oncology, 2022-04, Vol.165 (1), p.40-48

2022

Volltextzugriff (PDF)

Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study

Breast cancer research and treatment, 2012-05, Vol.133 (1), p.237-246

2012

Volltextzugriff (PDF)

The Aromatase Inhibitor Anastrozole Is Ineffective in the Treatment of Precocious Puberty in Girls with McCune-Albright Syndrome

The journal of clinical endocrinology and metabolism, 2008-07, Vol.93 (7), p.2751-2754

2008

Volltextzugriff (PDF)

Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma

Head & neck, 2016-03, Vol.38 (3), p.439-447

2016

Volltextzugriff (PDF)

Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

Obstetrical & gynecological survey, 2019-02, Vol.74 (2), p.86-87

2019

Volltextzugriff (PDF)

Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study

Cancer chemotherapy and pharmacology, 2012, Vol.69 (1), p.273-280

2012

Volltextzugriff (PDF)

Rubem Fonseca, Always

Review (Americas Society), 2021-01, Vol.54 (1), p.102-105

Parisot, Paula

2021

Volltextzugriff (PDF)

My Friend Rubem

Review (Americas Society), 2021-01, Vol.54 (1), p.106-113

Piñon, Nélida

2021

Volltextzugriff (PDF)

Gregory Rabassa, Eternal Master

Review (Americas Society), 2020-07, Vol.53 (2), p.271-274

Piñon, Nélida

2020

Volltextzugriff (PDF)

SOLO3: A randomized phase III trial of olaparib versuschemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (g BRCA m)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS5598-TPS5598

2016

Volltextzugriff (PDF)

1 – 25 von 887

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(734)
Mit Volltextzugriff
(718)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(484)
Life Sciences & Biomedicine
(419)
Humans
(340)
Female
(196)
Male
(150)
Adult
(97)
Middle Aged
(84)
Animals
(78)
Biological And Medical Sciences
(74)
Aged
(63)
Child
(59)
Medical Sciences
(59)
Adolescent
(53)
Social Sciences
(50)
Oncology
(44)
General & Internal Medicine
(43)
Science & Technology - Other Topics
(42)
Infectious Diseases
(40)
Multidisciplinary Sciences
(40)
Neurosciences & Neurology
(39)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(389)
EZB Electronic Journals Library
(362)
Ingenta
(341)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(292)
Publisher website
(219)
IngentaConnect Journals
(152)
ScienceDirect
(135)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(109)
Wiley Online Library
(90)
JSTOR
(80)
Wiley Online Library
(67)
Nature International Weekly Journal of Science
(57)
Ebook Central Perpetual and DDA
(51)
eBooks on EBSCOhost
(50)
SpringerLink_现刊
(48)
Nexis Uni (LexisNexis)
(47)
Oxford Journals
(43)
Taylor & Francis
(42)
Taylor & Francis Online
(41)
Taylor & Francis Journals
(37)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(32)
Nature
(15)
Review
(13)
Plos One
(11)
The Lancet
(10)
Library Journal
(9)
American Journal Of Infection Control
(8)
Diabetes Care
(7)
Nature Communications
(7)
Review - Center For Inter-American Relations
(7)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

Reply to S. Gulia et al

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial

Reply to E. Paulino et al

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study

Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study

The Aromatase Inhibitor Anastrozole Is Ineffective in the Treatment of Precocious Puberty in Girls with McCune-Albright Syndrome

Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma

Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study

Rubem Fonseca, Always

My Friend Rubem

Gregory Rabassa, Eternal Master

SOLO3: A randomized phase III trial of olaparib versuschemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (g BRCA m)

Suchergebnisse filtern